



RESULTS AT SENZIME AB'S (PUBL) EXTRAORDINARY GENERAL MEETING

Senzime AB (publ) held an extraordinary general meeting on March 5, 2018 in the premises of Advokatfirman Lindahl on Vaksalagatan 10 in Uppsala.

A. Resolution on directed share issue (No 1)

The general meeting resolved to issue new shares in accordance with the proposal by the board of directors. The resolution entails an increase of the Company's share capital with not more than SEK 447,917.0004 by an issue of not more than 3,583,336 new shares following the terms and conditions as set out below.

The right to subscribe for new shares shall, with deviation from the shareholders pre-emption rights, belong to the following persons/companies:

Subscriber	Number of shares	Subscription amount
Segulah Venture AB	2,500,000 shares	SEK 15,000,000
Mikael Lindskog	250,000 shares	SEK 1,500,000
Jerry Fredriksson	250,000 shares	SEK 1,500,000
Margareta Nilsson	133,334 shares	SEK 800,004
Anna Manhusen	133,334 shares	SEK 800,004
Crafoordska stiftelsen	133,334 shares	SEK 800,004
Carl Rosenblad	100,000 shares	SEK 600,000
Lennart Nilsson (via wholly-owned company)	83,334 shares	SEK 500,004
<i>Total:</i>	<i>3,583,336 shares</i>	<i>SEK 21,500,016</i>

The reason for the deviation from the shareholders' pre-emption rights is to acquire necessary funds to the Company, tie strategically important investors to the Company, strengthen the ownership base of the Company in order to increase the chances for a successful commercialization of the Company's products and additionally to accomplish a time and cost effective new issue of shares.

Subscription shall be made through payment not later than 7 March 2018. The board of directors shall have the right to extend the subscription and payment period.

The new shares are issued at a price of SEK 6 per share, which at full subscription means that the Company will receive SEK 21,500,016 (prior to issue costs).

The subscription price for the new shares has been negotiated with Segulah Venture AB and corresponds to a discount of 8 percent in comparison with the share weighted average price on the 10 latest trading days. Market conditions have been ensured through the mentioned negotiation and taking into account current market situation.

The new shares entitle to dividends for the first time on the first record date for dividend that take place after the issue of new shares has been registered with the Swedish

Companies Registration Office and been recorded in the share register kept by Euroclear Sweden AB.

B. Resolution on directed share issue (No 2)

The general meeting resolved to issue new shares in accordance with the proposal by the board of directors. The resolution entails an increase of the Company's share capital with not more than SEK 72,916.7501 by an issue of not more than 583,334 new shares following the terms and conditions as set out below.

The right to subscribe for new shares shall, with deviation from the shareholders pre-emption rights, belong to the following persons:

Subscriber	Number of shares	Subscription amount
Ulf Lindskog	400,000 shares	SEK 2,400,000
Adam Dahlberg	183,334 shares	SEK 1,100,004
<i>Total:</i>	<i>583,334 shares</i>	<i>SEK 3,500,004</i>

The terms and conditions of the share issue are the same as set out for the directed share issue under section A above.

All resolutions at the annual general meeting were adopted with the requisite majority.

For further information, please contact:

Lena Söderström, CEO of Sensime AB

Tel: +46 708-16 39 12, email: lena.soderstrom@sensime.com

Sensime AB (publ)

Board of directors

TO THE EDITORS

About Sensime

Sensime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients' neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Sensime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Sensime. www.sensime.com